Biotech & Medtech
Biotech & Medtech news — Wednesday 18 November 2026
28 stories from 4 sources, every one in English. Each links to its publisher.
-
Hone Health Secures $228M for Longevity Platform
Hone Health’s funding includes $28 million in equity as Series A financing, as well as $200 million in growth financing from General Catalyst’s Customer Value Fund. The post Hone Health Secures $228M for Longevity Platform appeared first…
-
STAT+: Epic Systems defends competitive practices, promises to let AI access its records
Executives at Epic Systems Corp., the largest maker of electronic health records, said Wednesday they would make it easier for companies to use artificial intelligence to read data stored in the company’s platforms, and defended Epic…
-
STAT+: Influential preventive services panel to meet for first time in more than a year
WASHINGTON — A little-known but influential panel that recommends which preventive services must be covered by insurance will meet this week for the first time in more than a year, with a membership overhauled by health secretary Robert F…
-
STAT+: NIH to move last group of its research chimps to a sanctuary
The last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year, a move that comes more than a decade after the National Institutes of Health agreed to end its funding for…
-
STAT+: 7 burning questions about the FDA’s post-Overton future
WASHINGTON — The White House pulled its nomination of Heidi Overton for commissioner of the Food and Drug Administration on Tuesday evening, startling senators on the health committee and introducing new questions about the future of the…
-
STAT+: The emerging winners and losers in the AI scribe market
This is the web edition of STAT’s AI Prognosis newsletter, our guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. Today’s the day! If you’re at HLTH, come down to the…
-
Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal
Pfizer gains global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics in preclinical development for undisclosed autoimmune diseases. It’s the latest in a series of big pharma business deals…
-
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH conference.
-
Abridge Announcements during HLTH Emphasize Growing Healthcare Trend
News emerging during the annual HLTH conference, including ones from Abridge, reflects the growing use of AI in clinical practice, emphasizing the need to bring clinical information into the workflows providers already use. The post…
-
White House pulls nomination for FDA nominee Overton
The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
-
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
-
STAT+: Cassidy rejects Trump’s pick to lead NSF, saying he failed to ‘stand up for science’
WASHINGTON — The Senate health panel on Wednesday rejected a top health official nominated to lead the National Science Foundation, with Chair Bill Cassidy (R-La.) expressing doubts about his willingness to stand up for scientific…
-
STAT+: FDA discloses reasons for rejecting Summit drug
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We got big news on the FDA last night — let’s get straight into it. White House pulls nomination of…
-
STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While…
-
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
-
I’ve Practiced Medicine for 40 Years — AI Gave Me Back My Evenings
If you’re a physician earlier in your career, the message is simple: whatever tools exist to get your evenings back, use them now, while you still have the evenings to spend them on. The post I’ve Practiced Medicine for 40 Years — AI Gave…
-
What redesigning medical school might look like
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Good morning. Our executive editor was dismayed yesterday when he learned that not everyone at STAT was familiar with this…
-
STAT+: Scientists heralded a blue wave. But will they miss Susan Collins?
Over the past six months, science advocates have been consumed by the fight over a White House proposal to subject all federal research contracts to more political oversight. Thousands of scientists and organizations have decried the…
-
Opinion: STAT+: RFK Jr. has got to go
The midterms didn’t just bring a blue wave — it was a biomedical blue wave, with several doctors and scientists joining Congress . This moment presents a unique opportunity to remove a major American public health problem. I’m talking…
-
Opinion: Maybe in-person four-year institutions aren’t the right approach to medical education
This article is part of a new First Opinion series on redesigning medical school. Over eight years as an M.D./Ph.D. student, I have watched medical education change considerably. Preclinical curricula have become shorter, lectures have…
-
Fully Spiking Neural Implementation of Lambda-Calculus Beta-Reduction via Biologically Documented Mechanisms
arXiv:2611.23182v1 Announce Type: cross Abstract: We present the first complete implementation of $\beta$-reduction in the untyped $\lambda$-calculus using exclusively spiking neural dynamics. Every step of the reduction---redex detection…
-
Diversity Preservation Recovers Transcription Factor Motifs Across Challenging Confounder Landscapes
arXiv:2611.21859v1 Announce Type: new Abstract: Motif discovery is a process where DNA sequences are searched for the short patterns, called motifs, that transcription factor (TF) proteins bind. However, the motif lengths are often unknown…
-
DeNA-SGN: Deterministic Neighborhood Aggregation for Verified Spiking Graph Inference
arXiv:2611.14775v2 Announce Type: replace Abstract: Graph learning on neuromorphic substrates requires an explicit spiking realization of neighborhood aggregation, supporting control and classification. We propose DeNA-SGN, which combines…
-
Multiobjective household energy planning using evolutionary algorithms
arXiv:2611.21668v1 Announce Type: new Abstract: This article presents the advances in the design and implementation of a recommendation system for planning the use of household appliances, focused on improving energy efficiency from the…
-
Evolving Neural Solvers for Multi-objective Combinatorial Optimization
arXiv:2611.22060v1 Announce Type: new Abstract: Multi-objective combinatorial optimization (MOCO) seeks high-quality solutions that represent different trade-offs among conflicting objectives. Existing neural methods typically train a…
-
EM-SDTrack: Efficient Multi-Scale Spike-driven Tracking for Event Cameras
arXiv:2611.22700v1 Announce Type: new Abstract: Event-driven spiking neural networks (SNNs) match the sparse spatiotemporal output of event cameras, making spike-driven trackers highly attractive for neuromorphic edge deployment. However…
-
Teladoc Launches Employer Contribution Option for GLP-1s
Teladoc launched a new offering that allows employers to contribute toward the cost of GLP-1 medications. The post Teladoc Launches Employer Contribution Option for GLP-1s appeared first on MedCity News .
-
STAT+: White House pulls nomination of Heidi Overton to lead FDA
WASHINGTON — The Trump administration is pulling its nominee to lead the Food and Drug Administration, Heidi Overton , according to a White House official and a source close to Overton. The decision follows concerns that Overton, a…